Table 3.
Results of the 5 separate Cox regression analyses to evaluate the prognostic factors associated with the risk of locoregional recurrence, contralateral breast cancer, metastases or 2nd cancer other than breast
| Characteristic | Locoregional recurrences | Contralateral breast cancer | Distant metastases | 2nd primary cancer other than breast | Breast cancer death | |||||
|---|---|---|---|---|---|---|---|---|---|---|
|
RR (95% CI) |
p |
RR (95% CI) |
P |
RR (95% CI) |
P |
RR (95% CI) |
p |
RR (95% CI) |
p | |
| Histological size of the tumor (for 1 mm increase) | 1.02 (0.99-1.06) |
0.17 | 1.02 (0.97-1.06) |
0.54 | 1.02 (1.00-1.05) |
0.08 | 1.01 (0.93-1.10) |
0.75 | 1.02 (0.99-1.05) |
0.27 |
| Extensive intraductal component (EIC) | ||||||||||
| - No (ref) | 1 | 1 | 1 | -- | 1 | |||||
| - Yes | 3.34 (0.89-12.5) |
0.07 | 0.99 (0.13-7.46) |
1.00 | 1.55 (0.34-7.06) |
0.57 | -- | -- | 1.43 (0.20-10.8) |
0.73 |
| Grade | ||||||||||
| - Grade1(ref) | 1 | 1 | 1 | 1 | 1 | |||||
| - Grade 2 |
1.84 (1.11-3.07) |
0.02 | 1.45 (0.78-2.70) |
0.24 |
2.68 (1.58-4.53) |
< 0.001 | 0.68 (0.23-2.01) |
0.48 |
3.64 (1.74-7.60) |
< 0.001 |
| - Grade 3 |
2.12 (1.17-3.84) |
0.01 | 0.94 (0.40-2.21) |
0.88 |
3.39 (1.91-6.02) |
< 0.001 | 1.32 (0.37-4.75) |
0.67 |
5.54 (2.58-11.9) |
< 0.001 |
| # positive nodes | ||||||||||
| - 0 (ref) | 1 | 1 | 1 | -- | 1 | |||||
| - 1-3 |
2.60 (1.30-5.19) |
0.007 | 1.17 (0.34-3.97) |
0.81 |
2.41 (1.29-4.47) |
0.006 | -- | -- |
2.92 (1.50-5.68) |
0.002 |
| - ≥4 |
4.40 (1.80-10.7) |
0.001 | 0.66 (0.13-3.45) |
0.62 |
6.91 (3.41-14.0) |
< 0.001 | -- | -- |
8.03 (3.71-17.4) |
< 0.001 |
| Lympho-vascular invasion | ||||||||||
| - No (ref) | 1 | 1 | 1 | 1 | 1 | |||||
| - Yes | 1.29 (0.84-1.98) |
0.24 |
0.41 (0.19-0.90) |
0.03 |
1.47 (1.04-2.08) |
0.03 | 1.40 (0.51-3.83) |
0.51 | 1.27 (0.87-1.91) |
0.26 |
| Surgical excision margin status | ||||||||||
| - Clear (ref) | 1 | 1 | 1 | 1 | 1 | |||||
| - Invasion | 0.95 (0.64-1.43) |
0.81 |
2.36 (1.40-3.98) |
0.001 | 1.05 (0.74-1.48) |
0.78 | 0.57 (0.19-1.73) |
0.32 | 1.12 (0.75-1.67) |
0.59 |
| Progesterone receptor status | ||||||||||
| -Positive(ref) | 1 | 1 | 1 | 1 | 1 | |||||
| - Negative | 1.26 (0.84-1.88) |
0.26 | 1.21 (0.70-2.09) |
0.49 | 1.32 (0.93-1.86) |
0.12 | 0.33 (0.11-1.03) |
0.06 |
1.90 (1.26-2.87) |
0.002 |
| Treatment combination | ||||||||||
| - Radiotherapy (ref) | 1 | 1 | 1 | -- | 1 | |||||
| - Radio- and chemotherapy |
0.23 (0.11-0.50) |
< 0.001 | 1.22 (0.33-4.55) |
0.77 | 0.52 (0.27-1.02) |
0.06 | -- | -- | 0.56 (0.27-1.16) |
0.12 |
| - Radio- and hormonal therapy |
0.35 (0.16-0.77) |
0.009 | 0.78 (0.21-2.91) |
0.71 | 0.59 (0.30-1.13) |
0.11 | -- | -- |
0.48 (0.24-0.99) |
0.05 |
| - Radio- and chemo- and hormonal therapy |
0.06 (0.01-0.49) |
0.008 | 0.74 (0.07-7.60) |
0.80 |
0.33 (0.11-0.99) |
0.05 | -- | -- | 0.28 (0.07-1.06) |
0.06 |
-- variables not included in the model